CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)

Nguyen H. Tran, Joseph J. Larson,Fang‐Shu Ou,Amit Mahipal,Shaylene McCue,Rondell P. Graham,Martín E. Fernández-Zapico,Alexander Revzin,Lionel Aurelien Kankeu Fonkoua,Lynn M. Flickinger,Sean P. Cleary,Tanios Bekaii‐Saab,Mitesh J. Borad,Robert R. McWilliams,Aminah Jatoi, Wen Wee

Journal of The National Comprehensive Cancer Network（2023）

引用 0|浏览9

暂无评分

摘要

"CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)" published on 31 Mar 2023 by National Comprehensive Cancer Network.

查看译文

关键词

fgfr inhibitor futibatinib,fgf19,pembrolizumab,metastatic hepatocellular carcinoma,hepatocellular carcinoma,single-arm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要